News

Patients with both COVID-19 and malignant pleural mesothelioma showed high rates of hospitalization and mortality.

While survival rates in T-cell acute lymphoblastic leukemia remain around 90%, researchers are optimistic that the use of targeted therapies and immunotherapies will continue to improve treatment options.

International lung cancer clinical trial sites reported that flexibilities in time and place were effective strategies to mitigate COVID–19-related patient concerns and to increase participation.

Selectively targeting the EGFR exon insertion mutations was associated with improved outcomes in patients with previously treated non-small cell lung cancer.

Chronic graft-versus-host disease management has continued to advance in recent years, with new and anticipated treatment options for its treatment landscape.

After the 3-arm, JAVELIN Ovarian 100 trial terminated at the interim analysis, researchers concluded that avelumab is not yet a suitable first-line treatment option for patients with advanced epithelial cancer.

The impact of animal-assisted therapy is felt by more than just patients with cancer, explained Cynthia Ingram, BS, RN, HN-BC, COHN-S. Service animals like her dog, Tori, can also have a positive impact on the well-being of caregivers and health care providers.

The ANA has issued a statement to the HHS imploring them to declare a national crisis.

Treatment with Roxadustat was associated with promising results in chemotherapy-induced anemia in non-myeloid malignancies.

The data showed that a daily intake of around 300 IU of vitamin D — roughly the same as three 8-oz. glasses of milk — was linked to a nearly 50% decreased risk of early-onset colorectal cancer among women between the ages of 25 and 42 years.

Nagla Abdel Karim, MD, explains how researchers will address safety and manage potential adverse events in the ongoing phase 3 CheckMate-73L trial.

Over half of the states in the United States have legalized medical cannabis. What does that mean for nurses who care for patients with cancer?

Multidisciplinary approaches are still needed to proactively address the high relapse rates in patients with ovarian cancer treated with platinum-based chemotherapies, says Sanaz Memarzadeh, MD, PhD.

Zanubrutinib (Brukinsa) is now FDA approved for the treatment of adults with Waldenström Macroglobulinemia.

Adherence to current clinical guidelines may contribute to systematic underdiagnosis in Black women, says Kemi M. Doll, MD, MS.

“It’s a Privilege, I feel very honored to be helping patients.”

A seroconversion rate of 94% was identified in a diverse cohort of patients with cancer who had received the COVID-19 vaccine.

Pembrolizumab has been granted full approval as a first-line treatment for a select population of patients with bladder cancer.

Newly standardized grading criteria will help to regulate the management of CAR T-cell therapy¬–related toxicities, like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).

Kelly Garvin, BSN, RN, OCN, discusses the impact of CAR T-cell therapy on patients and how nurses care for them, as well as her expectations on how indications will grow.

Increases were detected in all cancer screening procedures except for colonoscopies.

As patients with hematologic cancers live for normal life expectancies, the consequences associated with opioid use becomes more severe.

An official statement has been signed and issued by the National Comprehensive Cancer Center Network insisting that health care systems mandate COVID-19 immunizations for their workers

Identifying targets early can help forestall resistance and improve the efficacy of osimertinib, a EGFR tyrosine kinase inhibitor, in the first-line setting.

Tisagenlecleucel is a CAR T-cell therapy approved to treat follicular lymphoma that has minimal toxicity and is safe in the outpatient setting.

Small employment increases in March and February didn’t replenish the more than 80,000 jobs lost in January.

“There were delays in getting preventative screenings, there were delay in diagnostics, there was also a brief period of time when some of the clinical trials were shut down.”

The FDA approved ivosidenib as the first targeted therapy to treat patients with previously treated IDH1-mutated cholangiocarcinoma.